Key Drivers
- Strong FCF
- Manageable leverage
- Premium valuation
AIAI Summary
DGX is no longer a cheap defensive name but a “prove-it” story at a richer valuation, so the key investment question is whether Quest can sustain near-9% organic growth, stable margins, and strong cash flow enough to offset reimbursement pressure and added debt without multiple compression.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •Manageable leverage
- •Premium valuation
DGX is a stable cash-generating business with respectable margins and returns, but its leverage, heavy intangibles, and premium valuation leave limited margin of safety.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Tightening range
- •Failed rebounds
DGX remains in a short-term downtrend over the last month, but the pullback is tightening near $186.6–$190.9, hinting at a possible base unless it can reclaim $192.7–$195.0 with follow-through.
Recent bounces failed to recover the $195–$196 breakdown area
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Guidance Raise
- •Margin Pressure
Quest Diagnostics beat Q1 estimates, raised full-year guidance, and drew renewed investor interest, though margin and reimbursement risks still matter.
This news is bullish for DGX in the near term, as strong execution and upgraded outlook outweigh the lingering reimbursement and margin concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings